[News release – not published yet] Empagliflozin phase III EMPA-KIDNEY trial will stop early due to evidence of efficacy in people with chronic kidney disease.

Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease – Lilly

See also: Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial – Nephrology Dialysis Transplantation

Commentary on Twitter

Details of the design & pt characteristics now published:

6609 people from 8 countries
(UK, Germany, Italy, USA, Canada, China, Malaysia, Japan)
Mean age 64 years
1/3 female
1/2 diabetes; 1/2 without
3/4 eGFR <45 mL/min/1.73 m2.
1/2 uACR <300 mg/g https://t.co/jOD8kyp3i4 pic.twitter.com/YYpGPJDnV9

— Martin Landray (@MartinLandray) March 16, 2022